Department of Anesthesiology, Intensive Care and Pain Management, Maribor University Hospital, Maribor, Slovenia.
Wien Klin Wochenschr. 2010 May;122 Suppl 2:49-53. doi: 10.1007/s00508-010-1345-x.
Acute zoster pain usually disappears with regression of the rash but may be of significant intensity and prolonged duration leading to postherpetic neuralgia. We evaluated the effect of pregabalin on alleviation of acute zoster pain and onset of postherpetic neuralgia.
The prospective randomized double-blind placebo-controlled study included 29 outpatients who had had acute zoster pain for a period of 7-14 days. Patients were treated for three weeks with 150-300 mg pregabalin daily or with a placebo. Pain was treated with naproxen, tramadol or oxycodone, as necessary. During the treatment we assessed pain, allodynia, hyperalgesia, severity of burning, prickling and tingling sensations, quality of sleep, physical activity, consumption of analgesics, manifestation of adverse events and postherpetic neuralgia.
There were no statistically significant differences with respect to patients' demographic data, dermatomal distribution and severity of rash, use of antiviral therapy or duration of acute zoster pain. Standard statistical analyses found no significant differences between the two treatment groups in intensity of pain, allodynia, hyperalgesia, burning, prickling and tingling sensations, consumption of analgesics, or the quality of sleep and physical activity; there was also no significant difference in development of postherpetic neuralgia. However, there were statistically significant differences between the groups in the occurrence of dizziness and somnolence in relation to pregabalin.
The study did not prove any statistically significant effect of pregabalin in pain relief in patients with acute zoster pain or in the onset of postherpetic neuralgia in comparison with the placebo. The use of pregabalin was related to a statistically significant increase in the appearance of adverse effects.
急性带状疱疹疼痛通常随皮疹消退而消失，但也可能强度较大且持续时间较长，导致带状疱疹后神经痛。我们评估了普瑞巴林对缓解急性带状疱疹疼痛和带状疱疹后神经痛发病的影响。
前瞻性随机双盲安慰剂对照研究纳入了 29 名急性带状疱疹疼痛持续 7-14 天的门诊患者。患者接受为期 3 周的治疗，每天服用 150-300mg 普瑞巴林或安慰剂。必要时使用萘普生、曲马多或羟考酮治疗疼痛。在治疗过程中，我们评估了疼痛、感觉异常、痛觉过敏、烧灼感、刺痛感和刺痛感的严重程度、睡眠质量、身体活动、镇痛药的使用、不良反应的表现以及带状疱疹后神经痛。
两组患者的人口统计学数据、皮节分布和皮疹严重程度、抗病毒治疗的使用或急性带状疱疹疼痛持续时间均无统计学差异。标准统计分析发现，两组间疼痛强度、感觉异常、痛觉过敏、烧灼感、刺痛感和刺痛感、镇痛药的使用或睡眠和身体活动质量均无显著差异；带状疱疹后神经痛的发生也无显著差异。然而，与普瑞巴林相关的头晕和嗜睡在两组间存在统计学差异。
与安慰剂相比，该研究未证明普瑞巴林在缓解急性带状疱疹疼痛或带状疱疹后神经痛发病方面具有统计学显著效果。普瑞巴林的使用与不良反应的出现呈统计学显著增加相关。
